GlassScriptPhysician profile
Staci Fiock
NPI 1669213104
$3,691.63
in general payments reported to CMS, 2019-2025
28 companies · $2,381 in 2025
The $2,381 reported for 2025 was more than what 95% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,311 · 2025: $2,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,691.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $674.65 | 2024-2025 | |
| Ucb, INC. | $514.91 | 2024-2025 | Bimzelx, Cimzia |
| Amgen INC. | $500.39 | 2025 | Krystexxa, Otezla, Tavneos |
| Novartis Pharmaceuticals Corporation | $283.79 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $269.34 | 2024-2025 | Purified Cortrophin Gel, Sovuna |
| Glaxosmithkline, LLC. | $198.78 | 2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $168.63 | 2024-2025 | Acthar |
| Genzyme Corporation | $136.62 | 2025 | |
| Organon LLC | $104.78 | 2024-2025 | Hadlima |
| Lilly USA, LLC | $79.79 | 2024 | Taltz |
| Pfizer INC. | $78.54 | 2024-2025 | |
| Invivyd INC | $76.48 | 2025 | Pemgarda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.63 | 2024-2025 | Ofev |
| Octapharma USA, INC. | $67.64 | 2024-2025 | Octagam Immune Globulin (Human) |
| Radius Health, INC. | $60.18 | 2024-2025 | Tymlos |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $51.29 | 2024 | Tremfya, Simponi Aria |
| Fresenius Kabi USA, LLC | $46.41 | 2025 | Tyenne |
| Alexion Pharmaceuticals, INC. | $41.18 | 2024-2025 | Strensiq |
| Tersera Therapeutics LLC | $38.36 | 2025 | Quzyttir |
| Azurity Pharmaceuticals, INC. | $36.30 | 2024-2025 | Horizant |
| Kiniksa Pharmaceuticals International, Plc | $35.05 | 2024 | Arcalyst |
| Genentech USA, INC. | $32.71 | 2024-2025 | Actemra |
| E.R. Squibb & Sons, L.L.C. | $32.17 | 2025 | Orencia |
| Alnylam Pharmaceuticals INC. | $20.76 | 2024 | Givlaari |
| Kyowa Kirin, INC. | $19.07 | 2025 | |
| Aurinia Pharma U.S., INC. | $18.06 | 2024 | Lupkynis |
| Bioventus LLC | $16.37 | 2025 | Gelsyn-3 |
| Alvogen INC | $13.75 | 2025 | Teriparatide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Staci Fiock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.